Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019

J Infect Dis. 2022 Oct 21;226(Suppl 4):S407-S415. doi: 10.1093/infdis/jiac242.

Abstract

To describe the impact of the US varicella vaccination program on severe varicella outcomes, we analyzed varicella hospitalizations using the National Inpatient Sample 1993-2019 and varicella deaths using the National Center for Health Statistics data 1990-2019. Over 25 years of vaccination program (1995-2019), varicella hospitalizations, and deaths declined 94% and 97%, respectively, among persons aged <50 years. Most of the decline (∼90%) occurred during the 1-dose period (through 2006/2007) by attaining and maintaining high vaccination coverage; additional declines occurred during the 2-dose period, especially in the age groups covered by the 2-dose recommendation. The greatest decline for both hospitalizations and deaths (97% and >99%, respectively) was among persons aged <20 years, born during the varicella vaccination program. In the <20 age group, varicella hospitalization has become a rare event, and varicella deaths have been practically eliminated in the United States. A total of >10 500 varicella hospitalizations and 100 varicella deaths are now prevented annually in the United States as a direct result of vaccination and reduction in varicella-zoster virus circulation.

Keywords: VZV; Varicella; death; hospitalization; impact; mortality; program; vaccine.

MeSH terms

  • Adult
  • Chickenpox Vaccine
  • Chickenpox* / epidemiology
  • Chickenpox* / prevention & control
  • Herpes Zoster* / epidemiology
  • Herpes Zoster* / prevention & control
  • Herpesvirus 3, Human
  • Hospitalization
  • Humans
  • Infant
  • United States / epidemiology
  • Vaccination
  • Young Adult

Substances

  • Chickenpox Vaccine